Search
Menu

News

Discover the latest news stories, blog posts and publications from Cobra's expert team

Home / News

Posts by Tag

See all

or

Posts by Tag

See all
Posts about

vaccine

INTERVIEW: Ola Tuvesson discusses COVID-19 vaccine production with SVT

Företag i Matfors ska tillverka supermodernt coronavaccin

Links & Downloads: Cobra Articles

Peer Reviewed Publications A selection of links and downloadable magazine articles

Cobra Biologics selected to manufacture plasmids for clinical trial of Scancell’s COVID-19 vaccine

The collaboration will ensure GMP production of material for the Phase 1 clinical trial of Scancell’s DNA vaccine against SARS-CoV-2

BLOG: COVID-19 Vaccine Scaling Up and Scaling Out

My previous blog was written at the start of April, shortly after the UK had, like many other countries, moved into a period of “lockdown”. At the time there was in the region of 1.25m reported cases of COVID-19 and just over 60,000 deaths. Despite extensive lockdown scenarios across the globe, the numbers have now increased to over 14.5m cases, currently growing at rate of over 1m cases a week and over 600,000 deaths, however these numbers are

Cobra signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate

Providing large scale manufacturing capacity for AZD1222 Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. The production agreement is part of AstraZeneca’s recently announced

Cobra signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate

Providing large scale manufacturing capacity for AZD1222 Biologics manufacturing capacity and the challenges of scaling up vaccine production to fast track one million doses by September

INTERVIEW: Thomas Moore, Sky News, reports on the fight against COVID-19

Biologics manufacturing capacity and the challenges of scaling up vaccine production to fast track one million doses by September Biologics manufacturing capacity and the challenges of scaling up vaccine production to fast track one million doses by September

INTERVIEW: Andrew Marr with Prof. Sarah Gilbert, vaccinologist at Oxford University

Cobra is proud to be part of a consortium, led by the Jenner Institute, Oxford University to rapidly develop a COVID-19 vaccine Cobra is proud to be part of a consortium, led by the Jenner Institute, Oxford University to rapidly develop a COVID-19 vaccine

BLOG: COVID-19 Vaccine Hopes and Hurdles

Cobra has been fortunate to be given the opportunity to work with two novel vaccine candidates against COVID-19, utilising the company’s knowledge and experience in the production... Cobra Biologics has been fortunate to be given the opportunity to work with two novel vaccine candidates against COVID-19, utilising the company’s knowledge and experience in the production of plasmid DNA and viral vaccines. This blog aims to give a short introduction into the different types of vaccines that are in use, including the platform approaches relating to these two candidates and to highlight some of the potential manufacturing and

Cobra Biologics is proud to be part of a consortium to rapidly develop a COVID-19 vaccine

ChAdOx1 consortium, led by the Jenner Institute, working to produce adenoviral vaccine with a fast-tracked clinical trials to begin in April 2020

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

OPENCORONA consortium awarded €3million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak (Svensk version nedan)
1 2